A Review of Nebivolol Pharmacology and Clinical Evidence - Wikidata - wikimedia - TriplyDB

A Review of Nebivolol Pharmacology and Clinical Evidence

A Review of Nebivolol Pharmacology and Clinical Evidence

http://www.wikidata.org/entity/Q26801287

about

Bioequivalence study between a fixed-dose single-pill formulation of nebivolol plus hydrochlorothiazide and separate formulations in healthy subjects using high-performance liquid chromatography coupled to tandem mass spectrometry.Nebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis.Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction.Nebivolol Attenuates Neutrophil Lymphocyte Ratio: A Marker of Subclinical Inflammation in Hypertensive Patients.Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.Nebivolol attenuates oxidative stress and inflammation in a guinea pig model of ovalbumin-induced asthma: a possible mechanism for its favorable respiratory effects.Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study.Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.Functional characterization of CYP2C19 variants in nebivolol 4-hydroxlation in vitro.Evaluation of 24 CYP2D6 Variants on the Metabolism of Nebivolol In Vitro.Insights on β-blockers for the treatment of hypertension: A survey of health care practitioners

P2860

Q36181109-7D011768-7E96-400C-94B8-004CF782E291 Q37327436-67747FC0-E5F6-4CFC-8220-51901B866879 Q37632186-789863BA-6E6B-4C12-99C7-A3B2349B6F9D Q38618940-8FC7A43C-4AD6-4B47-85E0-70EADBB15536 Q39210212-3871543D-3991-4555-97DE-DC01857D70B0 Q47661286-765BF371-D5EC-4D80-A6B9-5BEBD4F7BC42 Q47813077-638FF3ED-4274-4173-B138-3E475BDF55EA Q48359964-65DA53F0-53B3-4456-9C4F-09923761E39D Q48369805-4B8BF1D7-2214-4E95-A799-A867DEFCBBF4 Q52855692-80711AD1-2BA3-4059-B897-1EED3CD13FE7 Q56981925-E09A014D-9A9F-4D11-9695-36B5CABF1424

P2860

A Review of Nebivolol Pharmacology and Clinical Evidence

http://www.wikidata.org/entity/Q26801287

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A Review of Nebivolol Pharmacology and Clinical Evidence

@ast

A Review of Nebivolol Pharmacology and Clinical Evidence

@en

A Review of Nebivolol Pharmacology and Clinical Evidence

@nl

type

label

A Review of Nebivolol Pharmacology and Clinical Evidence

@ast

A Review of Nebivolol Pharmacology and Clinical Evidence

@en

A Review of Nebivolol Pharmacology and Clinical Evidence

@nl

prefLabel

A Review of Nebivolol Pharmacology and Clinical Evidence

@ast

A Review of Nebivolol Pharmacology and Clinical Evidence

@en

A Review of Nebivolol Pharmacology and Clinical Evidence

@nl

P1433

Q26801287-54BAF68C-3CC6-4FF1-8263-220788100712

P1476

Q26801287-DA0286C9-2B45-458F-9C8E-97D3148DCCB3

P2093

Q26801287-585114BE-33DE-4389-B86E-8B35233BDE6F

Q26801287-935526A0-3E51-4244-8563-2BD9076D6E85

P2860

Q26801287-01552D72-DE26-4310-8F5E-021B09F85AAE

Q26801287-0755567B-E25D-456F-8447-B162BB746046

Q26801287-0B304439-9D17-429A-857A-9794940E277D

Q26801287-0D075AFE-8C10-4C11-932E-3CC32171648B

Q26801287-10C98351-5BA0-4663-ABFF-70F45D21E7E1

Q26801287-1126361A-9689-48FE-8EA5-8C6922FFFE9D

Q26801287-125DB4CF-DFB1-4331-9513-FB7CB9003875

Q26801287-1563C83D-64E3-4B85-BCF0-644CF589A96D

Q26801287-18749A35-49CA-48B1-9479-5E6068ED672E

Q26801287-1B354A48-A493-47E3-8620-CF74D31B9084

P2888

Q26801287-6438CDDF-C82A-4F22-B915-081F862EE34F

P304

Q26801287-9C0782CF-D5DF-4855-8373-E7D5D2452B30

P31

Q26801287-BF37070E-FC5A-44FA-B45F-7BDCB2136549

Q26801287-D59F71DF-6583-4928-B429-A1271FAFB37B

P3181

Q26801287-098F541A-70E6-4703-B944-2B919D28651B

P356

Q26801287-284E3704-71B0-49D7-A30F-D979D5AD9F3B

P407

Q26801287-AD4F3DB7-68A5-444B-BDF3-454E75D5E751

P433

Q26801287-3A925AFB-B660-4D92-87C1-8CD8AB13EFC1

P478

Q26801287-94A95E4E-70A3-43B3-8AB9-8C79C3958060

P577

Q26801287-05B13D47-CF58-45F5-ADEA-5BA17D3AA174

Q26801287-E3D00AAF-D1F5-4D5A-8834-50B39888149A

P5875

Q26801287-80DBD70A-73F0-4545-9BD3-2D0296F07B21

P6179

Q26801287-8296BBD1-CE7F-4C4D-8389-A6147BECB1CA

P698

Q26801287-C008E44F-505F-457F-B584-06CEC8C6513F

P921

Q26801287-4706BE29-76E0-4D9F-ACAE-E999D4977F30

Q26801287-851A2DF6-1780-4851-AC5C-181433502E52

Q26801287-91726755-9F24-4AFC-98E7-272E57143130

Q26801287-968510BB-76A9-4AD7-912B-094C81DE4714

Q26801287-B3DFD8CA-8C06-42E6-B177-82573DC15AB4

Q26801287-CF2E9A7C-ADAD-41AA-BD9B-3344C6335E1A

Q26801287-D75DDB16-2FD3-404B-981F-C132324C6687

P932

Q26801287-D1773FBC-A089-49CB-A773-FEEAF89142FE

P3181

P356

S40265-015-0435-5

P1433

P1476

A Review of Nebivolol Pharmacology and Clinical Evidence

@en

P2093

Erika Felix-Getzik

http://www.w3.org/2001/XMLSchema#string

Justin Fongemie

http://www.w3.org/2001/XMLSchema#string

P2860

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress.

Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial.

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

Role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the data.

P2888

s40265-015-0435-5

P304

1349-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4895292

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S40265-015-0435-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280121567

http://www.w3.org/2001/XMLSchema#string

P6179

1021158058

http://www.w3.org/2001/XMLSchema#string

P698

26177892

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

mechanism of action

arterial hypertension

P932

4541699

http://www.w3.org/2001/XMLSchema#string